Friday 6 November 2026 Export CORT’s income statement to Excel — free account

Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $761.4 million, up 12.8% from fiscal 2024.

Revenue: +64.0%
EPS: +525.8%
Free cash flow: +161.0%

Quarter to September 2026, against a year earlier

73.11 1.48 +2.07%

Follow CORT

Alert me

Market cap: $7.8B
P/E: 47.5×
Fwd P/E: 39.8×
Dividend yield: —
F-score: 4/9
Altman Z: 14.11
Beneish M: −2.76
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Valuation Filings

Corcept Therapeutics Incorporated (CORT) Price to free cash flow

Alert me on Price to free cash flow

As of 5 November 2026, Corcept Therapeutics Incorporated (CORT) trades at a price to free cash flow of 39.5×. Over the past ten years it has ranged from 0.0× (December 2015) to 171× (December 2015); the current reading is higher than 72% of that period. That is above the Biotechnology industry median of 24.8× and above the Healthcare sector median of 21.1×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/CORT/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="Corcept Therapeutics Incorporated price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/CORT/metrics/price-to-free-cash-flow">Corcept Therapeutics Incorporated (CORT) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2025	25.5×	(3.89%)
FY2024	26.5×	34.11%
FY2023	19.8×	10.10%
FY2022	18.0×	31.33%
FY2021	13.7×	(31.72%)
FY2020	20.0×	95.47%
FY2019	10.2×	(23.29%)
FY2018	13.4×	(60.75%)
FY2017	34.0×	(23.90%)
FY2016	44.7×	(73.85%)

Period	Price to free cash flow	Change
Sep 2026	63.1×	(26.33%)
Jun 2026	85.7×	144.57%
Mar 2026	35.0×	37.45%
Dec 2025	25.5×	(51.62%)
43 more quarters	Free account

Against its own ten years

Low 0.0× High 171×

Ten-year median 20.2×

Current reading's percentile 72

Company	Price to free cash flow
SYRE Spyre Therapeutics, Inc. compare	n/m
ABVX Abivax SA Sponsored ADR compare	n/m
PRAX Praxis Precision Medicines, Inc. compare	n/m
CYTK Cytokinetics, Incorporated compare	n/m
MDGL Madrigal Pharmaceuticals, Inc. compare	n/m
ARWR Arrowhead Pharmaceuticals, Inc. compare	n/m
KRYS Krystal Biotech, Inc. compare	28.7×
CORT Corcept Therapeutics Incorporated	39.5×
PTGX Protagonist Therapeutics, Inc. compare	68.3×
Biotechnology industry median	24.8×
Healthcare sector median	21.1×
Market median	14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

Corcept Therapeutics Incorporated (CORT) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on CORT

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on CORT

Stockrow Weekly